Resurgence and seasonal patterns of RSV-B during the COVID-19 era: an 18-year retrospective hospital-based study
- PMID: 40434592
- DOI: 10.1007/s10096-025-05178-6
Resurgence and seasonal patterns of RSV-B during the COVID-19 era: an 18-year retrospective hospital-based study
Abstract
Respiratory syncytial virus (RSV) is a leading cause of severe respiratory infections, particularly in infants, older adults, and immunocompromised individuals. In this study, we aimed to characterize the epidemiology of RSV subtype B (RSV-B), which remains relatively understudied compared with subtype A despite its clinical significance. We conducted a retrospective analysis of laboratory-confirmed RSV-B infections over 18 years (2007-2024) at a tertiary hospital in South Korea. The dataset included 23,284 cases analyzed for age distribution, seasonality, sex differences, and the impact of the coronavirus disease 2019 (COVID-19) pandemic. The highest positivity rate was observed in infants under 1 year (12.7%, p < 0.001), followed by ages 1-19 years (6.9%). RSV-B incidence peaked in winter (11.9%) and autumn (8.7%), with significant seasonal variation (p < 0.001). No statistically significant sex-based difference was observed (male: 6.1%, female: 6.7%; p = 0.102). Positivity rates declined markedly during the COVID-19 pandemic (2019-2022), likely due to non-pharmaceutical interventions. These findings clarify RSV-B's distinct epidemiology and underscore the need for subtype-specific surveillance, targeted vaccination, and adaptable public health strategies. This study provides evidence to improve outbreak prediction, identify high-risk groups, and optimize clinical and preventive responses to RSV-B.
Keywords: Adolescent; Disease outbreaks; Incidence; Infant; Prevalence; Respiratory syncytial virus.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical approval: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Dankook University (Approval No. DKU 2025-02-004-003). The IRB waived the requirement for informed consent due to the retrospective nature of the study. Consent to participate: Patient consent was waived because the research relied on data obtained from diagnostic tests conducted by medical institutions and did not involve any personal patient information. Competing interests: The authors declare no competing interests.
References
-
- Li Y, Wang X, Blau DM et al (2022) Global, regional, and National disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399:2047–2064. https://doi.org/10.1016/S0140-6736(22)00478-0 - DOI - PubMed - PMC
-
- Alfano F, Bigoni T, Caggiano FP, Papi A (2024) Respiratory syncytial virus infection in older adults: an update. Drugs Aging 41:487–505. https://doi.org/10.1007/s40266-024-01118-9 - DOI - PubMed - PMC
-
- Nuttens C, Moyersoen J, Curcio D et al (2024) Differences between RSV A and RSV B subgroups and implications for pharmaceutical preventive measures. Infect Dis Ther 13:1725–1742. https://doi.org/10.1007/s40121-024-01012-2 - DOI - PubMed - PMC
-
- Contes KM, Liu BM (2025) Epidemiology, clinical significance, and diagnosis of respiratory viruses and their co-infections in the post-COVID era. Pathogens 14:262. https://doi.org/10.3390/pathogens14030262 . PMID: 40137747
-
- Lakshmanan K, Liu BM (2025) Impact of point-of-care testing on diagnosis, treatment, and surveillance of vaccine-preventable viral infections. Diagnostics (Basel) 15:123. https://doi.org/10.3390/diagnostics15020123 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
